Yes, you can give Lyrica (pregabalin) with Cymbalta (duloxetine)
The combination of pregabalin and duloxetine is safe, well-tolerated, and commonly used together for neuropathic pain conditions, particularly diabetic peripheral neuropathy. Both medications work through complementary mechanisms without significant pharmacokinetic interactions, and clinical guidelines explicitly support their combined use when monotherapy provides inadequate pain relief 1.
Safety Profile
The FDA drug label for Lyrica confirms that pregabalin has no significant pharmacokinetic drug interactions and does not undergo meaningful metabolism or protein binding that would interfere with other medications 2. Pregabalin is predominantly excreted unchanged in the urine, making drug-drug interactions unlikely from a pharmacological standpoint.
Clinical Evidence for Combination Therapy
Recent high-quality evidence strongly supports combining these medications:
A 2026 systematic review and meta-analysis demonstrated that pregabalin plus duloxetine produced significantly greater pain relief than monotherapy (mean difference = -1.82, p<0.00001) in painful diabetic neuropathy, with no significant increase in overall adverse events 3
The landmark COMBO-DN study (2013), a multinational randomized controlled trial, found the combination to be effective, safe, and well-tolerated, with 50% response rates of 52.1% for combination therapy versus 39.3% for high-dose monotherapy 4
Multiple recent studies (2023-2025) consistently show the combination improves pain scores, quality of life, and sleep without prohibitive side effects 5, 6, 7
Guideline Recommendations
Mayo Clinic neuropathic pain guidelines explicitly recommend combination therapy as a standard approach 1:
- When patients achieve only partial pain relief with one first-line medication (duloxetine or pregabalin), guidelines recommend adding the other first-line medication rather than switching
- Both duloxetine (an SSNRI) and pregabalin (a calcium channel α2δ ligand) are designated as first-line therapies
- The stepwise approach specifically states: "If partial pain relief after an adequate trial, add one of the other first-line medications"
Mechanism Rationale
The combination works through complementary, non-overlapping mechanisms 8:
- Pregabalin reduces excitatory neurotransmission by binding to voltage-gated calcium channels (α2δ subunit), inhibiting neurotransmitter release
- Duloxetine enhances descending noradrenergic and serotonergic inhibitory pathways in the central nervous system
- Together, they address both peripheral and central pain mechanisms
Practical Prescribing
Start each medication at standard doses and titrate based on response 1:
- Duloxetine: Start 30 mg once daily for 1 week, then increase to 60 mg once daily (maximum 60 mg twice daily if needed)
- Pregabalin: Start 50 mg three times daily or 75 mg twice daily, increase to 300 mg/day after 3-7 days (maximum 600 mg/day)
When combining, you can use lower doses of each medication to minimize side effects while maintaining efficacy. Recent evidence shows a fixed-dose combination of low-dose pregabalin (75 mg twice daily) plus duloxetine (30 mg twice daily) achieved similar analgesia to high-dose pregabalin monotherapy (150 mg twice daily) with comparable tolerability 7.
Important Caveats
Monitor for additive CNS effects:
- Both medications can cause dizziness and somnolence
- The FDA label notes that pregabalin shows additive effects on cognitive and gross motor functioning when combined with CNS depressants, though no specific interaction with duloxetine is mentioned 2
- Start low and titrate slowly to minimize these effects
Adjust pregabalin dose in renal impairment (creatinine clearance <60 mL/min), as it is renally excreted 2
Common side effects to counsel patients about:
- Dizziness and somnolence (both medications)
- Nausea (duloxetine, especially in first week)
- Peripheral edema and weight gain (pregabalin more than duloxetine)
- Dry mouth (duloxetine)
The combination is particularly valuable when monotherapy at standard doses provides insufficient pain relief after an adequate trial (4 weeks for duloxetine, 4 weeks for pregabalin at target dose) 1.